mbiomics
Decoding the microbiome to redefine therapeutics
United States · Founded 2020 · $12.0M raised
- Founded
- 2020
- Business Model
- B2B
- Website
- mbiomics.com
- Total Funding
- $12.0M
- Last Round
- $12.0M Series AMay 2026
- Rounds
- 2
About
mbiomics is a Neuried/Munich, Germany-based biotechnology company that designs and manufactures Live Biotherapeutic Products (LBPs) — rationally selected consortia of 100+ gut bacterial strains — to restore healthy microbial ecosystems and treat severe, chronic diseases. Its lead program, MBX-116, is a checkpoint-inhibitor co-therapy designed to boost immunotherapy response in advanced melanoma, with additional pipeline targets in inflammatory bowel disease and autism spectrum disorder. The company expanded its Series A to EUR 30 million in April 2026 and also operates a US entity, mbiomics Inc., in Boston, Massachusetts.
Summary
mbiomics is a Biotech company based in United States, founded in 2020. It has raised $12.0M in total across 2 rounds, most recently a $12.0M Series A round in May 2026. Investors include MIG AG, High-Tech Grunderfonds and Bayern Kapital.
Funding History
May 2026
Sign up to see all 2 rounds
Series A — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/mbiomics"><img src="https://indexed.vc/api/badge/company/mbiomics" alt="mbiomics on Indexed.vc" width="260" height="76" /></a>